Cargando…

Cabozantinib and dasatinib synergize to induce tumor regression in non-clear cell renal cell carcinoma

The lack of effective treatment options for advanced non-clear cell renal cell carcinoma (NCCRCC) is a critical unmet clinical need. Applying a high-throughput drug screen to multiple human kidney cancer cells, we identify the combination of the VEGFR-MET inhibitor cabozantinib and the SRC inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Lue, Hui-wen, Derrick, Daniel S., Rao, Soumya, Van Gaest, Ahna, Cheng, Larry, Podolak, Jennifer, Lawson, Samantha, Xue, Changhui, Garg, Devin, White, Ralph, Ryan, Christopher W., Drake, Justin M., Ritz, Anna, Heiser, Laura M., Thomas, George V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149375/
https://www.ncbi.nlm.nih.gov/pubmed/34095877
http://dx.doi.org/10.1016/j.xcrm.2021.100267
Descripción
Sumario:The lack of effective treatment options for advanced non-clear cell renal cell carcinoma (NCCRCC) is a critical unmet clinical need. Applying a high-throughput drug screen to multiple human kidney cancer cells, we identify the combination of the VEGFR-MET inhibitor cabozantinib and the SRC inhibitor dasatinib acts synergistically in cells to markedly reduce cell viability. Importantly, the combination is well tolerated and causes tumor regression in vivo. Transcriptional and phosphoproteomic profiling reveals that the combination converges to downregulate the MAPK-ERK signaling pathway, a result not predicted by single-agent analysis alone. Correspondingly, the addition of a MEK inhibitor synergizes with either dasatinib or cabozantinib to increase its efficacy. This study, by using approved, clinically relevant drugs, provides the rationale for the design of effective combination treatments in NCCRCC that can be rapidly translated to the clinic.